ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

REGN Regeneron Pharmaceuticals Inc

1,094.99
12.88 (1.19%)
17 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Regeneron Pharmaceuticals Inc NASDAQ:REGN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  12.88 1.19% 1,094.99 1,056.35 1,100.00 1,100.08 1,079.0855 1,087.89 282,365 01:00:00

Statement of Changes in Beneficial Ownership (4)

21/04/2020 12:27am

Edgar (US Regulatory)


FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

LAROSA JOSEPH J
2. Issuer Name and Ticker or Trading Symbol

REGENERON PHARMACEUTICALS, INC. [ REGN ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
EVP General Counsel and Secret
(Last)          (First)          (Middle)

777 OLD SAW MILL RIVER ROAD
3. Date of Earliest Transaction (MM/DD/YYYY)

4/16/2020
(Street)

TARRYTOWN, NY 10591
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 4/16/2020  M(1)  5000 A$59.2 19438 D  
Common Stock 4/16/2020  F(1)  2733 D$529.79 16705 D  
Common Stock 4/17/2020  S(1)  95 D$541.94 16610 D  
Common Stock 4/17/2020  S(1)  5 D$542.31 16605 D  
Common Stock 4/17/2020  S(1)  100 D$547.0 16505 D  
Common Stock 4/17/2020  S(1)  99 D$548.27 16406 D  
Common Stock 4/17/2020  S(1)  100 D$549.24 16306 D  
Common Stock 4/17/2020  S(1)  6 D$550.0 16300 D  
Common Stock 4/17/2020  S(1)  104 D$552.85 16196 D  
Common Stock 4/17/2020  S(1)  114 D$555.1 16082 D  
Common Stock 4/17/2020  S(1)  198 D$556.51 (2)15884 D  
Common Stock 4/17/2020  S(1)  93 D$557.4 15791 D  
Common Stock 4/17/2020  S(1)  293 D$558.55 (3)15498 D  
Common Stock 4/17/2020  S(1)  285 D$559.79 (4)15213 D  
Common Stock 4/17/2020  S(1)  163 D$560.38 (5)15050 D  
Common Stock 4/17/2020  S(1)  63 D$561.76 14987 D  
Common Stock 4/17/2020  S(1)  191 D$562.56 (6)14796 D  
Common Stock 4/17/2020  S(1)  171 D$563.39 (7)14625 D  
Common Stock 4/17/2020  S(1)  93 D$564.19 14532 D  
Common Stock 4/17/2020  S(1)  94 D$565.92 (8)14438 D  
Common Stock 4/17/2020  M(1)  6622 A$59.2 21060 D  
Common Stock 4/17/2020  F(1)  3602 D$555.82 17458 D  
Common Stock 4/17/2020  M(1)  5000 A$59.2 22458 D  
Common Stock 4/17/2020  F(1)  2720 D$555.82 19738 D  
Common Stock 4/20/2020  S(1)  51 D$561.57 19687 D  
Common Stock 4/20/2020  S(1)  21 D$562.71 19666 D  
Common Stock 4/20/2020  S(1)  416 D$563.58 (9)19250 D  
Common Stock 4/20/2020  S(1)  377 D$564.74 (10)18873 D  
Common Stock 4/20/2020  S(1)  1468 D$565.6 (11)17405 D  
Common Stock 4/20/2020  S(1)  1189 D$566.44 (12)16216 (13)D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares

Explanation of Responses:
(1) Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
(2) Represents volume-weighted average price of sales of 198 shares of Company stock on April 17, 2020 at prices ranging from $556.43 to $556.58. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price.
(3) Represents volume-weighted average price of sales of 293 shares of Company stock on April 17, 2020 at prices ranging from $558.42 to $558.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price.
(4) Represents volume-weighted average price of sales of 285 shares of Company stock on April 17, 2020 at prices ranging from $559.47 to $559.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price.
(5) Represents volume-weighted average price of sales of 163 shares of Company stock on April 17, 2020 at prices ranging from $560.27 to $560.53. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price.
(6) Represents volume-weighted average price of sales of 191 shares of Company stock on April 17, 2020 at prices ranging from $562.31 to $562.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price.
(7) Represents volume-weighted average price of sales of 171 shares of Company stock on April 17, 2020 at prices ranging from $563.33 to $563.45. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price.
(8) Represents volume-weighted average price of sales of 94 shares of Company stock on April 17, 2020 at prices ranging from $565.77 to $565.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price.
(9) Represents volume-weighted average price of sales of 416 shares of Company stock on April 20, 2020 at prices ranging from $563.35 to $563.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price.
(10) Represents volume-weighted average price of sales of 377 shares of Company stock on April 20, 2020 at prices ranging from $564.03 to $564.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price.
(11) Represents volume-weighted average price of sales of 1,468 shares of Company stock on April 20, 2020 at prices ranging from $565.03 to $565.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price.
(12) Represents volume-weighted average price of sales of 1,189 shares of Company stock on April 20, 2020 at prices ranging from $566.00 to $566.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 20, 2020 at each separate price.
(13) Form one of two

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
LAROSA JOSEPH J
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591


EVP General Counsel and Secret

Signatures
/s/**Joseph J. LaRosa4/20/2020
**Signature of Reporting PersonDate

1 Year Regeneron Pharmaceuticals Chart

1 Year Regeneron Pharmaceuticals Chart

1 Month Regeneron Pharmaceuticals Chart

1 Month Regeneron Pharmaceuticals Chart

Your Recent History